B Cell Lymphoma Trials


Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL

The recruitment status of this study is unknown because the information has not been verified recently. Verified June 2010 by Asan Medical Center.   Recruitment status was  Recrui…

Continue reading about Clinical Trial Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL

A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma

This study is currently recruiting participants. Verified August 2012 by Hoffmann-La Roche First Received on January 31, 2011.   Last Up…

Continue reading about Clinical Trial A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma

Abbreviated R-CHOP in Completely Excised Stage I DLBCL

This study is currently recruiting participants. Verified January 2012 by Asan Medical Center First Received on August 3, 2010.   Last U…

Continue reading about Clinical Trial Abbreviated R-CHOP in Completely Excised Stage I DLBCL

Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma

This study is ongoing, but not recruiting participants. First Received on October 19, 2009.   Last Updated on July 3, 2012   History of Changes …

Continue reading about Clinical Trial Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin’s Lymphoma

A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

This study is currently recruiting participants. Verified June 2012 by MedImmune LLC First Received on October 3, 2011.   Last Updated o…

Continue reading about Clinical Trial A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom’s Macroglobulinemia

This study is currently recruiting participants. Verified May 2011 by Avila Therapeutics First Received on May 10, 2011.   Last Updated …

Continue reading about Clinical Trial Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom’s Macroglobulinemia

A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma Who Are Candidates for Autologous Stem Cell Transplant

This study has been terminated. ( Investigator left institution. 7 patients accrued and there is insufficient data to analyze. ) First Received on August 9, 2007. …

Continue reading about Clinical Trial A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma Who Are Candidates for Autologous Stem Cell Transplant

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

This study is currently recruiting participants. Verified July 2012 by Millennium Pharmaceuticals, Inc. First Received on July 1, 2009.   …

Continue reading about Clinical Trial Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)

This study has been withdrawn prior to enrollment. ( The NAVIGATE study has been terminated due to non-safety related reasons. ) First Received on August 24, 2011….

Continue reading about Clinical Trial A Study of Navitoclax in Addition to Bendamustine and Rituximab in Patients With Relapsed Diffuse Large B-Cell Lymphoma (NAVIGATE)

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

This study is currently recruiting participants. Verified July 2012 by Astellas Pharma Inc First Received on January 25, 2011.   Last Up…

Continue reading about Clinical Trial Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)